Glenmark Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Revenue	175,838	167,114	133,217	118,131	115,832	123,049
Other Revenue	1,528	2,711	415.54	8,323	723.29	-
Revenue	177,366	169,825	133,633	126,454	116,556	123,049
Revenue Growth	32.94%	27.08%	5.68%	8.49%	-5.28%	12.44%
Cost of Revenue	49,777	47,475	45,250	45,789	44,108	45,481
Gross Profit	127,589	122,350	88,383	80,665	72,448	77,568
Selling, General & Admin	37,498	35,779	36,814	34,465	31,833	29,176
Other Operating Expenses	42,124	40,848	27,639	25,924	23,541	25,124
Operating Expenses	85,789	82,361	69,314	66,208	61,066	59,168
Operating Income	41,800	39,989	19,069	14,457	11,382	18,400
Interest Expense	-2,045	-2,087	-2,071	-5,160	-3,490	-2,981
Interest & Investment Income	-	-	439.41	61.78	73.52	97.85
Currency Exchange Gain (Loss)	-	-	282.27	-	2,035	880.54
Other Non Operating Income (Expenses)	4,999	4,606	-	-	-	688.35
EBT Excluding Unusual Items	44,754	42,508	17,720	9,359	10,000	17,086
Gain (Loss) on Sale of Assets	-	-	-	15.3	57.25	-64.64
Legal Settlements	-	-	-	-	-8,011	-
Other Unusual Items	-19,429	-22,661	-3,728	-9,010	351.99	-2,609
Pretax Income	25,326	19,847	13,992	364.95	2,398	14,412
Income Tax Expense	7,348	6,228	3,521	18,673	3,294	4,476
Earnings From Continuing Operations	17,978	13,620	10,471	-18,309	-895.61	9,936
Earnings From Discontinued Operations	-	-	-	3,973	4,670	-
Net Income to Company	17,978	13,620	10,471	-14,335	3,774	9,936
Minority Interest in Earnings	0.97	-1.01	-0.45	-681.46	-801.55	-519.38
Net Income	17,979	13,619	10,471	-15,017	2,972	9,417
Net Income to Common	17,979	13,619	10,471	-15,017	2,972	9,417
Net Income Growth	138.54%	30.06%	-	-	-68.44%	-2.92%
Shares Outstanding (Basic)	282	282	282	282	282	282
Shares Outstanding (Diluted)	282	282	282	282	282	282
Shares Change	-0.00%	0.03%	0.01%	0.00%	-	-
EPS (Basic)	63.72	48.26	37.11	-53.22	10.53	33.37
EPS (Diluted)	63.69	48.24	37.11	-53.22	10.53	33.37
EPS Growth	138.55%	30.00%	-	-	-68.43%	-2.93%

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Free Cash Flow	-	20,873	-15,772	-11,638	176.29	3,185
Free Cash Flow Per Share	-	73.94	-55.89	-41.24	0.63	11.29
Dividend Per Share	2.500	5.000	2.500	2.500	2.500	2.500
Dividend Growth	-	100.00%	0%	0%	0%	0%
Gross Margin	71.94%	72.05%	66.14%	63.79%	62.16%	63.04%
Operating Margin	23.57%	23.55%	14.27%	11.43%	9.77%	14.95%
Profit Margin	10.14%	8.02%	7.84%	-11.88%	2.55%	7.65%
Free Cash Flow Margin	-	12.29%	-11.80%	-9.20%	0.15%	2.59%
EBITDA	48,317	45,724	21,676	18,297	14,289	19,124
EBITDA Margin	27.24%	26.92%	16.22%	14.47%	12.26%	15.54%
D&A For EBITDA	6,517	5,735	2,607	3,840	2,907	723.93
EBIT	41,800	39,989	19,069	14,457	11,382	18,400
EBIT Margin	23.57%	23.55%	14.27%	11.43%	9.77%	14.95%
Effective Tax Rate	29.01%	31.38%	25.16%	5116.72%	137.34%	31.06%
Revenue as Reported	182,365	174,431	134,355	126,531	118,721	124,716
Advertising Expenses	-	-	6,079	5,157	5,270	4,349